Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Nanobiotix, a clinical-stage nanomedicine firm, has secured €9m funding from bpifrance, formerly known as OSEO, of which €2.8m is directly attributable to the company.
Subscribe to our email newsletter
Granted through bpifrance’s Strategic Industrial Innovation (ISI) program, the funding is to expedite the clinical and industrial development of NBTXR3 in a new indication, liver cancer.
Liver cancer is a major health problem that causes one of the greatest number of deaths each year worldwide, 695,000 deaths per annum.
This grant supports the launch of Nano Innovation for Cancer (NICE), which is the first Medicen Paris Region accredited consortium of nanomedicine stakeholders in France, concentrating on the characterization and industrialization aspects of nanodrugs.
NICE consortium comprises five public and private companies, including BioAlliance Pharma, CEA-Leti, DBI and the Institut Galien Paris Sud (University Paris Sud/CNRS) and Nanobiotix.
The consortium aims to create a platform to speed up the development and industrialization of nanomedicine in France.
NanoXray-based liver cancer drug NBTXR3 is currently under clinical development for advanced soft tissue sarcoma and has the French Medicine Agency, ANSM has approved to start a second clinical trial in patients.
Nanobiotix CEO and co-founder Laurent Levy said, "Today, nanomedicine is considered as one of the major growth drivers of the global pharmaceutical industry and it is essential that the industry is structured at the local level to be competitive."
Strategic Industrial Innovation (ISI) program supports ambitious, innovative collaborative projects through to industrialization, driven by new medium-sized companies and small businesses.